Corcept Therapeutics Incorporated
CORT
Clasificación en acciones
#1698
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Precio por acción
$116.87
Última sincronización: 2026-10-20
Capitalización bursátil
$12.63B
Cambio (1 día)
4.25%
Cambio (1 año)
55.01%
País
US
Comercio Corcept Therapeutics Incorporated (CORT)
Categoría
Healthcare
Ingresos de Corcept Therapeutics Incorporated (CORT)
Ingresos en Jun 2026 TTM: $830.81M
Según los últimos informes financieros de Corcept Therapeutics Incorporated, los ingresos actuales de la empresa (TTM) son $830.81M. En 2023, la empresa obtuvo unos ingresos de $482.38M un aumento con respecto a los ingresos del año 2022, que fueron de $401.86M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Corcept Therapeutics Incorporated desde 2001 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $830.81M | 23.08% |
| 2024 | $675.04M | 39.94% |
| 2023 | $482.38M | 20.04% |
| 2022 | $401.86M | 9.80% |
| 2021 | $365.98M | 3.42% |
| 2020 | $353.87M | 15.46% |
| 2019 | $306.49M | 21.99% |
| 2018 | $251.25M | 57.82% |
| 2017 | $159.20M | 95.77% |
| 2016 | $81.32M | 61.72% |
| 2015 | $50.29M | 89.39% |
| 2014 | $26.55M | 156.36% |
| 2013 | $10.36M | 213.18% |
| 2012 | $3.31M | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | -100.00% |
| 2009 | $29.00K | -86.12% |
| 2008 | $209.00K | -56.64% |
| 2007 | $482.00K | 63.95% |
| 2006 | $294.00K | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $2.54B | 205.24% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $4.88B | 487.88% |
HK
|
